Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
Date:11/9/2009

edically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types, with a Phase 3 in multiple myeloma, under Special Protocol Assessment (SPA), pending commencement by year-end. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, and Keryx is in the process of finalizing the U.S. Phase 3 program for Zerenex in consultation with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to complete cost-effective clinical trials or meet the projected development timelines for the drug candidates in our
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
3. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
4. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
5. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
6. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
7. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
9. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
10. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
11. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... July 21, 2014 ... Market Research "E-Clinical Solution Software Market- Global Industry Analysis, ... the global microfluidic device market was valued at USD ... at a CAGR of 13.8% from 2014 to 2020, ... in 2020. Browse the full E-Clinical Solution ...
(Date:7/21/2014)... LAS VEGAS , July 21, 2014 By ... Division will conduct an online sale of ophthalmic and optical ... Las Vegas -based eyewear specialists American Optical Services LLC. ... and will close in rapid succession, live auction style, ... the various assets being offered will be held July 25 ...
(Date:7/21/2014)... , July 21, 2014  Zacks.com announces the list of ... Equity Research analysts discuss the latest news and events impacting ... blog include the Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH - Free ... ), Eli Lilly and Company (NYSE: LLY - Free ... and InterMune, Inc. (Nasdaq: ITMN - Free Report ). ...
Breaking Medicine Technology:E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 2E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 3E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 4E-Clinical Solution Software Market is expected to reach USD 6,515.3 million in 2020: Transparency Market Research 5Auction Set For Assets Of National Optical Services Company 2The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 2The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 3The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 4The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 5The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 6The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune 7
... 2012 Tris Pharma, an emerging specialty pharmaceutical company ... Dr. Mahdi Fawzi to its leadership position as the ... including Regulatory Affairs.   Throughout his career ... exemplified having many blockbuster drugs developed under his leadership ...
... 24, 2012  Mevion Medical Systems announced today that it ... and its existing investors, including Caxton Heath Life Sciences, ... of the MEVION S250 Proton Therapy System. The capital ... deployment of the MEVION S250. Proton ...
Cached Medicine Technology:Tris Pharma Announces Appointment of Dr. Mahdi Fawzi as Top R&D Executive 2Leading Private Venture Capital Firms Invest $45 Million in Mevion Medical Systems 2Leading Private Venture Capital Firms Invest $45 Million in Mevion Medical Systems 3
(Date:7/22/2014)... (PRWEB) July 22, 2014 Cumberland ... providing a dental experience that values anxiety-free dental care ... is essential for a child's dental care. , ... standard of care to infants, adolescents, adults and those ... emotional or physical disability, or require unique care, such ...
(Date:7/22/2014)... 2014 NOVAtime Technology, Inc. ( ... and Attendance / Workforce Management solutions, announced today ... customer since 2007, has upgraded to NOVAtime ... state-of-the-art, web-based time and attendance / workforce management ... is a human services agency that provides support ...
(Date:7/22/2014)... 2014 CareTouch Communications, Inc. has formed ... the Community . CareTouch employees will select causes they ... support in line with their mission to help people ... program’s first cause is Hike for Hospice, to benefit ... Sunday, September 14, the CareTouch in the Community team ...
(Date:7/22/2014)... The hair transplant experts at ... robotic assisted laser therapy and robotic assisted hair ... and women suffering from hair loss. Alongside their ... Follicular Unit Extraction (FUE) procedures via ARTAS – ... new technology, their doctors use advanced digital mapping ...
(Date:7/22/2014)... Manhattan Beach, CA (PRWEB) July 22, 2014 ... high-intensity interval training, olympic weightlifting, plyometrics, powerlifting, gymnastics, kettleball ... a normal workout. , Jason Sobzcak, co-owner of ... chooses EnergyFirst’s products because extreme workouts like ... on the Paleo diet so I need to take ...
Breaking Medicine News(10 mins):Health News:Cumberland Pediatric Dentistry and Orthodontics of Clarksville Welcomes Dr. Peter Wojtkiewicz, Pediatric Orthodontist 2Health News:Cumberland Pediatric Dentistry and Orthodontics of Clarksville Welcomes Dr. Peter Wojtkiewicz, Pediatric Orthodontist 3Health News:Lutheran Services in Iowa Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution; Benefits from Labor Costing Functionality 2Health News:Lutheran Services in Iowa Upgrades to NOVAtime 4000 Time and Attendance / Workforce Management Solution; Benefits from Labor Costing Functionality 3Health News:CareTouch is a Peak Sponsor for the 9th Annual Hike for Hospice in Morrison, Colorado 2Health News:WeGrowHair.com/PAI Medical Group Introduces Robotic Assisted Laser Therapy to Treat Hair Loss 2Health News:CrossFit East Cobb Fuels Their Intense Workouts with All-Natural EnergyFirst Supplements 2Health News:CrossFit East Cobb Fuels Their Intense Workouts with All-Natural EnergyFirst Supplements 3
... (HealthDay News) -- Some people may lose sleep over the ... are being pushed by female friends to lose weight or ... is a significant amount of research in other areas regarding ... pressure as it relates to sleep health is a less-explored ...
... 14, 2011 News media registration is now open ... Exposition in Denver, Aug. 28-Sept. 1, 2011. The event will ... and health, food and nutrition, energy, the environment, and other ... One of the largest scientific conferences of 2011, the meeting ...
... European Society of Cardiology (ESC) Working Group of Atherosclerosis and ... profile of vulnerable plaques and the need for greater use ... published online today in Thrombosis and Haemostasis , is ... rupture, and for the development of better diagnostics and treatments. ...
... MONDAY, June 13 (HealthDay News) -- A new poll finds ... the government-sponsored health insurance program for older Americans needs major ... to a Harris Interactive/HealthDay poll conducted in ... part, by lowering the fees paid to drug companies, hospitals ...
... class schedule with later start times allows colleges students to ... stay out drinking at night. As a result, their ... that will be presented Tuesday, June 14, in Minneapolis, Minn., ... Professional Sleep Societies LLC (APSS). Results show that later ...
... has a significant association with feelings of external pressure ... girls, especially those who are white, suggests a research ... Minneapolis, Minn., at SLEEP 2011, the 25th Anniversary Meeting ... Results show that pressures to have a thin body ...
Cached Medicine News:Health News:Young Girls May Lose Sleep Over Pressure to Be Thin 2Health News:ESC calls for research into vulnerable plaques 2Health News:Poll Finds Little Support for GOP Plan to Privatize Medicare 2Health News:Poll Finds Little Support for GOP Plan to Privatize Medicare 3Health News:College students sleep longer but drink more and get lower grades when classes start later 2Health News:White adolescent girls may be losing sleep from the pressure to be thin 2
The SleepStyle 600 series with ThermoSmart delivers humidification with anti-rainout benefits. ThermoSmart technology offers a heated breathing tube that allows the constant delivery of optimal level...
The S8 Escape is the economy model of ResMeds S8 series. The S8 Escape is ideal for patients who want the convenience and portability of the S8 models but do not require the added comfort features of...
... REMstar Plus with C-Flex combines ... and the comfort of C-Flex.With ... REMstar Plus with C-Flex offers ... deliver sleep therapy by taking ...
... a display, ramp capabilities and ... has features that make set-up ... meter records the number of ... four hours - giving you ...
Medicine Products: